// App-Quantinova.ai

2220 : Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Researchers

Presenter

  • Jan A. Burger

Principal Investigators

  • Tadeusz Robak

  • Fatih Demirkan

  • Osnat Bairey

  • Carol Moreno

  • David Simpson

  • Talha Munir

  • Don A. Stevens

  • Sandra Dai

  • Leo W. K. Cheung

  • Kevin Kwei

  • Indu Lal

  • Emily Hsu

  • Thomas J. Kipps

  • Alessandra Tedeschi

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

  • Division of Hematology, Dokuz Eylul University, Izmir, Turkey

  • Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel

  • Hospital de la Santa Creu i Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain

  • North Shore Hosp, Auckland, New Zealand

  • St. James's University Hospital, Leeds, United Kingdom

  • Norton Cancer Institute, Louisville, KY

  • Pharmcyclics LLC, an AbbVie Company, Sunnyvale, CA

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Niguarda Hospital, Milano, Italy

Locations

  • United States

  • Poland

  • Turkey

  • Israel

  • Spain

  • New Zealand

  • United Kingdom

  • Italy

Companies

  • Pharmacyclics LLC

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • Neurogenic locus notch homolog protein 1

  • Baculoviral IAP repeat-containing protein3

  • Exportin 1

  • Immunoglobulin heavy-chain variable region gene

  • Tumor protein p53

  • Splicing Factor 3b Subunit 1

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Ibrutinib

  • TP53

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01722487

  • NCT02264574

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved